Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Globe Newswire•12/10/2026•08:05 ET
0
Key Highlights
- ➤UC Phase 1a/1b: all five patients responded; two achieved clinical remission
- ➤FSCD Phase 1b: SES-CD fell 47.5%; two of five achieved endoscopic remission
- ➤PALI-0008 ileal and colonic tissue concentrations were approximately sevenfold above peak plasma
- ➤30 mg once daily maintained PALI-0008 exposure above estimated PDE4 IC90 for 24 hours
- ➤ASCENTRA-UC Phase 2 will test 15 mg and 30 mg once daily versus placebo in approximately 204 patients
Expert Statements
Mitch Jones, President and Chief Medical Officer of Palisade Bio
“These findings connect the key elements of our development strategy: delivering active drug to diseased intestinal tissue, engaging PDE4, and observing early clinical activity alongside reductions in inflammation.”
Mitch Jones, President and Chief Medical Officer of Palisade Bio
“The tissue analyses strengthen the mechanistic foundation for the clinical signals observed in UC and fibrostenotic Crohn’s disease, while our microbiome and biomarker work supports the delivery platform and a potential path toward more informed patient selection.”
Mitch Jones, President and Chief Medical Officer of Palisade Bio
“As we advance our Phase 2 programs, the two Presidential Poster Awards are meaningful recognition of the work of our investigators and collaborators.”
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development
Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts
Get started
Create a free account to read the full story.